The invention provides a prefilled syringe containing Hyoscine butylbromide which eliminates the risk of contamination and material loss. The present syringe being prefilled contains the concentration and the amount of frusemide required for the treatment. Therefore, the present syringe is not required to be filled from the drug ampoules and so, there are no chances of the drug getting exposed to the atmospheric contaminants leading to infections and further to health risks. Unlike the commonly used syringes, the present syringe is not made up of glass and hence it has no risks of breakage and associated material loss. Also it does not require glass ampoules to be filled from and hence there are no risks of breakage of the said ampoules leading to material loss.
